1 ML denosumab-bmwo 60 MG/ML Prefilled Syringe [Stoboclo]
- RxCUI
- 2717862
- RxNorm name
- 1 ML denosumab-bmwo 60 MG/ML Prefilled Syringe [Stoboclo]
- Display name
- 1 ML denosumab-bmwo 60 MG/ML Prefilled Syringe [Stoboclo]
- Full name
- 1 ML denosumab-bmwo 60 MG/ML Prefilled Syringe [Stoboclo]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:47
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761404 | Stoboclo | denosumab-bmwo | 351(k) Interchangeable | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Stoboclo | DENOSUMAB-BMWO | CELLTRION USA, Inc. | 10b9eea3-bf70-4ff3-a0b9-54248cbfd156 | 2026-02-05 | Boxed warning, Warnings, Adverse reactions | 2717862 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 10b9eea3-bf70-4ff3-a0b9-54248cbfd156 | 1 ML denosumab-bmwo 60 MG/ML Prefilled Syringe [Stoboclo] | SBD | 7 | These highlights do not include all the information needed to use STOBOCLO safely and effectively. See full prescribing information for STOBOCLO. STOBOCLO ® (denosumab-bmwo) injection, for subcutaneous use Initial U.S. Approval: 2025 STOBOCLO ® (denosumab-bmwo) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20260205 |
| 10b9eea3-bf70-4ff3-a0b9-54248cbfd156 | Stoboclo 60 MG per 1 ML Prefilled Syringe | SY | 7 | These highlights do not include all the information needed to use STOBOCLO safely and effectively. See full prescribing information for STOBOCLO. STOBOCLO ® (denosumab-bmwo) injection, for subcutaneous use Initial U.S. Approval: 2025 STOBOCLO ® (denosumab-bmwo) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20260205 |
| 10b9eea3-bf70-4ff3-a0b9-54248cbfd156 | Stoboclo 60 MG in 1 ML Prefilled Syringe | PSN | 7 | These highlights do not include all the information needed to use STOBOCLO safely and effectively. See full prescribing information for STOBOCLO. STOBOCLO ® (denosumab-bmwo) injection, for subcutaneous use Initial U.S. Approval: 2025 STOBOCLO ® (denosumab-bmwo) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20260205 |
| 10b9eea3-bf70-4ff3-a0b9-54248cbfd156 | 1 ML Stoboclo 60 MG/ML Prefilled Syringe | SY | 7 | These highlights do not include all the information needed to use STOBOCLO safely and effectively. See full prescribing information for STOBOCLO. STOBOCLO ® (denosumab-bmwo) injection, for subcutaneous use Initial U.S. Approval: 2025 STOBOCLO ® (denosumab-bmwo) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20260205 |